SCHEMBL4036979

SCHEMBL4036979

O=S(=O)(NC1CC1)c1c(Cl)cccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
KDM4E B2RXH2 2/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.43
PKLR P30613 1/20 0.43
KMT2A Q03164 3/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
PARG Q86W56 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ATM Q13315 1/20 0.41
MAPT P10636 1/20 0.41
P2RX7 Q99572 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13673266 0.88 ALDH1A1 (0.50) ALDH1A1L3MBTL1KDM4ERECQLSMN1; SMN2
SCHEMBL23052284 0.84 ALDH1A1 (0.47) ALDH1A1L3MBTL1PKMPKLRKMT2A
SCHEMBL4031272 0.80 ALDH1A1 (0.66) ALDH1A1L3MBTL1KDM4ELMNAKMT2A
SCHEMBL4030282 0.79 ALDH1A1 (0.87) ALDH1A1L3MBTL1KDM4ERECQLSMN1; SMN2
SCHEMBL3811143 0.76 USP30 (0.66)
SCHEMBL3811135 0.76 USP30 (0.66)
SCHEMBL6564302 0.75 ALDH1A1 (0.41) ALDH1A1L3MBTL1KDM4ERECQLSMN1; SMN2
SCHEMBL10453953 0.74 ALDH1A1 (0.77) ALDH1A1L3MBTL1KDM4ERECQLSMN1; SMN2
SCHEMBL6565738 0.73 KMT2A (0.48) ALDH1A1L3MBTL1KDM4ERECQLSMN1; SMN2
SCHEMBL4587287 0.73 CXCR2 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521744-B1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS FOURNIER LAB SA (FR) 2009-04-01 EP disclosed
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
CN-1484633-A N (phenylsulphonyl) glycine derivatives and their therapentic use ʵ���Ҹ���Ү��˾ 2004-03-24 CN disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 ALDH1A1 73/4885L3MBTL1 4830/4885KDM4E 3264/4885
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB ALDH1A1 2730/4885L3MBTL1 2774/4885KDM4E 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.